Chemotherapeutic and targeted biological agents for metastatic bladder cancer: A comprehensive review

International Journal of Urology

Volumn 21, Issue 7, 2014, Pages 630-637

  Sio, Terence T ^a   Ko, Jocelyn ^b   Gudena, Vinay K ^c   Verma, Nitin ^d   Chaudhary, Uzair B ^d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d Department of Hematology/Oncology Kaiser Permanente ^*  (United States)

Author keywords

Chemotherapy; Cisplatin; Metastatic bladder cancer; Targeted biological therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; LONAFARNIB; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PEMETREXED; SORAFENIB; SUNITINIB; TRASTUZUMAB; VINBLASTINE; VINFLUNINE;

ADVANCED CANCER; ALOPECIA; ALTERNATIVE MEDICINE; BLADDER CANCER; BLADDER METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; FUNCTIONAL STATUS; HEART DISEASE; HUMAN; KIDNEY DISEASE; MONOTHERAPY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; SECONDARY; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DOXORUBICIN; HUMANS; METHOTREXATE; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84903576582     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12407     Document Type: Review

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012; 62: 10-29.
2. Bajorin DF, Dodd PM, Mazumdar M etal. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 1999; 17: 3173-3181.
3. Yagoda A. Progress in treatment of advanced urothelial tract tumors. J. Clin. Oncol. 1985; 3: 1448-1450.
4. Stoter G, Splinter TA, Child JA etal. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J. Urol. 1987; 137: 663-667.
5. Harker WG, Meyers FJ, Freiha FS etal. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J. Clin. Oncol. 1985; 3: 1463-1470.
6. Sternberg CN, Yagoda A, Scher HI etal. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 1985; 133: 403-407.
7. Saxman SB, Propert KJ, Einhorn LH etal. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 1997; 15: 2564-2569.
8. Stadler WM, Kuzel TM, Raghavan D etal. Metastatic bladder cancer: advances in treatment. Eur. J. Cancer 1997; 33 (Suppl 1): S23-26.
9. Logothetis CJ, Dexeus FH, Finn L etal. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 1990; 8: 1050-1055.
10. Loehrer PJ Sr, Einhorn LH, Elson PJ etal. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 1992; 10: 1066-1073.
11. von der Maase H, Hansen SW, Roberts JT etal. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000; 18: 3068-3077.
12. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977; 39: 1362-1371.
13. Kemp G, Rose P, Lurain J etal. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 1996; 14: 2101-2112.
14. Dash A, Galsky MD, Vickers AJ etal. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107: 506-513.
15. Wittes RE, Brescia F, Young CW, Magill GB, Golbey RB, Krakoff IH. Combination chemothereapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology 1975; 32: 202-207.
16. Bamias A, Tiliakos I, Karali MD, Dimopoulos MA. Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann. Oncol. 2006; 17: 553-561.
17. Xu N, Zhang XC, Xiong JP etal. A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium. BMC Cancer 2007; 7: 98.
18. Bamias A, Lainakis G, Kastritis E etal. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. Oncology 2007; 73: 290-297.
19. Dreicer R, Manola J, Roth BJ etal. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004; 100: 1639-1645.
20. Bellmunt J, Ribas A, Eres N etal. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997; 80: 1966-1972.
21. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. Oncol. 2001; 19: 2527-2533.
22. Galsky MD, Iasonos A, Mironov S, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 2007; 109: 549-555.
23. Vaughn DJ, Malkowicz SB, Zoltick B etal. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J. Clin. Oncol. 1998; 16: 255-260.
24. Von der Maase H, Lehmann J, Gravis G etal. A phase II trial of pemetrexed plus gemcitabine as first-line treatment for locally advanced or metastatic transitional cell cancer of the urothelium. Procedures of American Society of Clinical Oncology 2005.
25. Bennouna J, Breton JL, Tourani JM etal. Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br. J. Cancer 2006; 94: 1383-1388.
26. Meluch AA, Greco FA, Burris HA III etal. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J. Clin. Oncol. 2001; 19: 3018-3024.
27. Srinivas S, Guardino AE. A nonplatinum combination in metastatic transitional cell carcinoma. Am. J. Clin. Oncol. 2005; 28: 114-118.
28. Li J, Juliar B, Yiannoutsos C etal. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J. Clin. Oncol. 2005; 23: 1185-1191.
29. Gitlitz BJ, Baker C, Chapman Y etal. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 2003; 98: 1863-1869.
30. Chaudhary U, Gudena V, Clark H etal. A phase II trial of gemcitabine and irinotecan in patients with metastatic bladder cancer. Genitourinary Cancers Symposium- ASCO 2008.
31. Carles J, Esteban E, Climent M etal. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann. Oncol. 2007; 18: 1359-1362.
32. Ricci S, Galli L, Chioni A etal. Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. Cancer 2002; 95: 1444-1450.
33. Chaudhary UB, Verma N, Keane T, Gudena V. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer. Am. J. Clin. Oncol. 2012; doi: 10.1097/COC.0b013e318271b306.
34. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92: 2993-2998.
35. Fechner G, Siener R, Reimann M, Kobalz L, Albers P. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int. J. Clin. Pract. 2006; 60: 27-31.
36. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int. 2008; 101: 20-25.
37. Sridhar SS, Winquist E, Eisen A etal. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest. New Drugs 2011; 29: 1045-1049.
38. Wulfing C, Machiels JP, Richel DJ etal. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115: 2881-2890.
39. Bellmunt J, Gonzalez-Larriba JL, Prior C etal. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann. Oncol. 2011; 22: 2646-2653.
40. Gallagher DJ, Milowsky MI, Gerst SR etal. Phase II study of sunitinib in patients with metastatic urothelial cancer. J. Clin. Oncol. 2010; 28: 1373-1379.
41. Kassouf W, Luongo T, Brown G, Adam L, Dinney CP. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J. Urol. 2006; 176: 787-792.
42. Wulfing C, Machiels J, Richel D etal. A single arm, multicenter, open label phase II study of lapatinib as 2L treatment of locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Procedures of American Society of Clinical Oncology 2005.
43. Hussain M, Petrylak D, Dunn R etal. (eds) Transtuzumab (T), paclitaxel (P), carboplatin (C) and gemcitabine (G) in advanced Her-2 positive urithelial carcinoma; results from a multicenter phase II NCI trial. Procedures of American Society of Clinical Oncology 2005.
44. Theodore C, Geoffrois L, Vermorken JB etal. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur. J. Cancer 2005; 41: 1150-1157.
45. Sridhar S, Stadler W, Lee D etal. (eds) Phase II study of bortezomib in advanced or metastatic urothelial cancer: a trial of the Princess Margaret Hospitals consortium. Procedures of American Society of Clinical Oncology 2005.